Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
